Superior survival among patients with <5 CTCs was observed regardless of histology, hormone receptor and HER2/neu status, sites of first metastases, or whether the patient had relapse or de novo metastatic disease (Cristofanilli et al, 2004; Dawood et al, 2008). This evidence concerns the gene ERBB2 and metastatic neoplasm.